New study investigates if smart insulin pumps reduce disordered eating in diabetes
NCT ID NCT07348432
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether newer automated insulin delivery systems help people with type 1 diabetes have healthier eating behaviors. Researchers will survey over 100 youth and adults across Canada about their eating habits and blood sugar control. The goal is to understand if these technologies reduce the burden of carbohydrate counting and lower the risk of eating disorders.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 106 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jul 2024
- Expected to finish
-
May 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
People living with type 1 diabetes
- Ages
-
12 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * 12 years of age or older * Living in Canada * Living with type 1 diabetes for more than 1 year * Using at least 2 insulin injections per day or using an insulin pump * Using current insulin delivery system for 3 months or more Exclusion Criteria: * Are pregnant or currently are breastfeeding * Don't speak French or English * Does not have a smart phone (to download applications)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Autoimmune diseases are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
McGill University
RECRUITINGMontreal, Quebec, H9X 3V9, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Clinical and biological responses to repeated administration of low-dose Interleukin-2 in patients with type 1 diabetes and a residual insulin secretion
- Can a smart insulin pump tailored for pregnancy protect mothers and babies?
- Can an automated pancreas system make type 1 diabetes safer in the real world?
- A new way to dose insulin without carb counting?
- Can a new teaching mix boost Doctors' confidence in endocrine crises?
- A finger prick instead of a needle: could At-Home blood tests match hospital accuracy?